000			01386 a2200373 4500
005			20250513094500.0
264		0	_c19961024
008			199610s 0 0 eng d
022			_a1064-1963
024	7		_a10.3109/10641969609088984 _2doi
040			_aNLM _beng _cNLM
100	1		_aBorghi, C
245	0	0	_aPrimary and secondary prevention of myocardial infarction. _h[electronic resource]
260			_bClinical and experimental hypertension (New York, N.Y. : 1993) _c
300			_a547-58 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAdrenergic beta-Antagonists _xtherapeutic use
650	0	4	_aAngiotensin-Converting Enzyme Inhibitors _xtherapeutic use
650	0	4	_aCalcium Channel Blockers _xtherapeutic use
650	0	4	_aCholesterol _xblood
650	0	4	_aClinical Trials as Topic
650	0	4	_aCoronary Disease _xdrug therapy
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aHyperlipidemias _xdrug therapy
650	0	4	_aHypertension _xdrug therapy
650	0	4	_aMale
650	0	4	_aMyocardial Infarction _xdrug therapy
650	0	4	_aRisk Factors
650	0	4	_aSmoking Cessation
700	1		_aAmbrosioni, E
773	0		_tClinical and experimental hypertension (New York, N.Y. : 1993) _gvol. 18 _gno. 3-4 _gp. 547-58
856	4	0	_uhttps://doi.org/10.3109/10641969609088984 _zAvailable from publisher's website
999			_c8740096 _d8740096